All In Biotech

Drug Trial Radar · NCT00389675

DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)

Last checked: Nov 20, 2026Latest source record: Jan 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

661

Actual

Start

May 2007

Primary completion

Feb 2010

Study completion May 2010

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Oct 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 35 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, active-controlled, long-term study of a new experimental drug called darusentan. Darusentan in not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to evaluate the long-term safety of darusentan (optimized dose) as compared to an active control, administered orally.

Conditions

  • Hypertension

Interventions

  • DarusentanDrug

    Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily

  • GuanfacineDrug

    Guanfacine 1 mg capsules administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean 24-hour systolic and diastolic ambulatory blood pressureTime frame: Baseline to Week 14
  2. Percentage of subjects who reach systolic blood pressure goalTime frame: Week 14
  3. Change from baseline in estimated glomerular filtration rate (eGFR)Time frame: Baseline to Week 14

Locations

99 sites in 4 countries. Site status is shown where the registry gives one.

  • Alabama Internal Medicine, PC

    Birmingham, Alabama

  • Greystone Medical Research, LLC

    Birmingham, Alabama

  • The Heart Center, PC

    Huntsville, Alabama

  • Mulberry Medical Associates, PC

    Montgomery, Alabama

  • Arizona Center for Clinical Research

    Glendale, Arizona

  • Cardiovascular Consultants, Ltd.

    Glendale, Arizona

  • Lovelace Scientific Resource, Inc.

    Phoenix, Arizona

  • Cochise Clinical Research

    Sierra Vista, Arizona

  • Southwest Heart

    Tucson, Arizona

  • HealthFirst Physicians of AR, PA dba Convenient Care Clinic

    Hot Springs, Arkansas

  • NEA Clinical

    Jonesboro, Arkansas

  • Arkansas Primary Care Clinic, PA

    Little Rock, Arkansas

  • Medical Investigators, Inc.

    Little Rock, Arkansas

  • Highgrove Medical Center

    Bakersfield, California

  • Central Cardiology Medical Clinic

    Bakersfield, California

  • Impact Clinical Trials

    Beverly Hills, California

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • Rancho Cucamonga Clinical Trials

    Rancho Cucamonga, California

  • Pacific Heart Institute

    Santa Monica, California

  • Los angeles biomedical research Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Aurora Denver Cardiology Associates

    Aurora, Colorado

  • Aurora Denver Cardiology Associates

    Denver, Colorado

  • Clinical Research of South Florida

    Coral Gables, Florida

  • Doctors Medical center of Walton County

    DeFuniak Springs, Florida

  • Broward General Medical Center

    Fort Lauderdale, Florida

  • Maxine Hamilton, MD, PA

    Fort Lauderdale, Florida

  • St John's Center for Clinical Research

    Jacksonville, Florida

  • Private Practice of Dr. Bridget Bellingar

    Largo, Florida

  • A + Research Inc.

    Miami, Florida

  • AppleMed Research, Inc.

    Miami, Florida

  • Internal Medicine Associates of South Florida

    North Miami Beach, Florida

  • Ormond Medical Arts Pharmaceutical Research Center

    Ormond Beach, Florida

  • Nothwest Florida Heart Group, PA-Research Dept

    Pensacola, Florida

  • Cardiovascular Center of Sarasota

    Sarasota, Florida

  • Suncoast Cardiovascular Research, Inc

    St. Petersburg, Florida

  • Tampa Bay Nephrology Associates, PL

    Tampa, Florida

  • Orlando Rangel, MD, PA

    Tampa, Florida

  • AMR Research Associates, LLC

    Bogart, Georgia

  • Atlanta Vascular Research Foundation

    Tucker, Georgia

  • Consultants in Cardiovascular Med (CIS)

    Melrose Park, Illinois

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.